Physician profile
Misty L Sinclair
NPI 1215993803
$161,484.28
in general payments reported to CMS, 2019-2025
59 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $45K · 2021: $16K · 2022: $8,579 · 2023: $1,155 · 2024: $1,320 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,920.69 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $77,611.96 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Allergan, INC. | $56,367.46 | 2019-2021 | |
| Genzyme Corporation | $19,616.97 | 2019-2021 | |
| Abbvie INC. | $3,107.43 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $511.22 | 2019-2024 | |
| Pfizer INC. | $431.17 | 2019-2025 | |
| Biogen, INC. | $351.60 | 2019-2025 | Vumerity, Leqembi |
| Ucb, INC. | $269.83 | 2019-2024 | Nayzilam, Rystiggo |
| Lilly USA, LLC | $240.20 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Lundbeck LLC | $227.71 | 2019-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $208.05 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $190.03 | 2021 | |
| Amgen INC. | $172.26 | 2019-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $166.01 | 2022 | |
| Upsher-Smith Laboratories LLC | $148.77 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.